The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPz Cussons Regulatory News (PZC)

Share Price Information for Pz Cussons (PZC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 102.00
Bid: 101.20
Ask: 102.80
Change: -2.00 (-1.92%)
Spread: 1.60 (1.581%)
Open: 103.40
High: 105.80
Low: 102.00
Prev. Close: 104.00
PZC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

22 Sep 2021 07:00

RNS Number : 5280M
PZ CUSSONS PLC
22 September 2021
 

22 September 2021

 

Returning to growth and continued strategic progress

 

PZ Cussons plc ("PZ Cussons" or the "Group") today issues the following trading update in respect of its first quarter of the new financial year to 31 May 2022, ended 28 August 2021.

 

 

Performance Highlights

 

§ As expected, unprecedented demand for our Hygiene brands at the beginning of the Covid-19 pandemic impacted year-on-year revenue comparisons in the first quarter of FY22.

 

§ Two-year Q1 revenue (1) grew +13%, with growth across each of our core categories of Hygiene, Baby and Beauty and in all geographic regions. Must Win Brands were up +23%.

 

§ One-year Q1 revenue (1) declined -9%, driven by Hygiene. The Baby and Beauty categories showed strong price / mix improvement, with Hygiene held back by unusually low levels of promotional discounting on Carex in the prior year.

 

§ Total business performance improved as the quarter progressed and we returned to growth in August. Assuming no further disruption, we expect to return to growth for Q2.

 

§ Must Win Brands declined -20% versus the prior year. Excluding Carex, revenue grew +4%.

 

- The decline was entirely driven by our Hygiene category, with Carex in the UK experiencing double-digit decline. The UK washing & bathing category has shown encouraging momentum as we emerge from Covid-19 restrictions. Carex is the clear market leader in hand hygiene, with revenue up over 40% versus two years ago.

- Sales of Baby products were flat. Covid-19 restrictions in Indonesia weighed more heavily than expected but are starting to moderate.

- Beauty grew double-digit, including our hair brands recovering from social restrictions.

 

§ Net debt reduced further in the first quarter of the new financial year, down to £23m, due in part to the proceeds from the five:am disposal, further narrowing our Food & Nutrition portfolio.

 

§ Despite the significant inflationary pressure on our cost base, assuming no further cost headwinds or global supply or other Covid-related disruption, we expect to deliver FY22 adjusted profit before tax within the current range of expectations.

 

 

Delivering our new strategy: Building brands for life. Today and for future generations

 

§ Q1 marketing investment increased over 20%, with the majority of the spend on Must Win Brands.

 

§ As input cost pressures increase, we have successfully executed price increases across our brand portfolios in Nigeria and Indonesia. In our developed markets, in addition to more targeted price increases, our Revenue Growth Management focus has been to drive brand equity improvements and efficient levels of price promotion to enable further price / mix improvements.

 

§ Simplification of our Nigerian business, including halving our supplier base and consolidating our distribution centres.

 

§ Continued progress developing capabilities and evolving our culture. Building on improved employee engagement scores we have launched a new company purpose, appointed new senior leaders and started a transformation programme to upgrade our people processes and systems.

 

 

Jonathan Myers, Chief Executive Officer, commented:

 

"The medium-term outlook remains in line with our expectations and we have confidence that our brand and market portfolio will emerge strongly once we cycle through the unprecedented demand for hygiene products at the start of the pandemic.

 

We continue to navigate the well-publicised inflationary pressures on commodities and freight. We have a co-ordinated effort underway to reduce product, manufacturing and logistics costs that the consumer does not value while also accelerating our Revenue Growth Management plans to drive price / mix. Combined with sustained and more effective marketing investment, stronger brand plans and new product innovation, these interventions mean that, assuming no further disruptions, we expect to return to growth for Q2 and to deliver low to mid single-digit revenue growth for the year, in line with our strategic financial framework we outlined at the Capital Markets Day in March. Despite the significant inflationary pressure on our cost base, assuming no further cost headwinds or global supply or other Covid-related disruption, we expect to deliver FY22 adjusted profit before tax within the current range of expectations."

 

Quarter 1

Revenue (£m)

Two-year growth (1)

One-year growth (1)

Europe & Americas

42.4

+7%

(28%)

Asia Pacific

40.4

+3%

(5%)

Africa

47.5

+31%

+15%

Central

1.1

(24%)

(51%)

Group

131.4

+13%

(9%)

 

(1) Revenue growth is quoted on a like-for-like organic basis, after the impact of acquired and disposed of brands or businesses, and at constant currency. Two-year growth rates included due to the short-term distorting effect of Covid-19.

 

Notes to editors

Figures are unaudited, and not subject to review by the Group's auditors

 

Cautionary note regarding forward-looking statements

This announcement contains certain forward-looking statements relating to expected or anticipated results, performance or events. Such statements are subject to normal risks associated with the uncertainties in our business, supply chain and consumer demand along with risks associated with macro-economic, political and social factors in the markets in which we operate. Whilst we believe that the expectations reflected herein are reasonable based on the information we have as at the date of this announcement, actual outcomes may vary significantly owing to factors outside the control of the Group, such as cost of materials or demand for our products, or within our control such as our investment decisions, allocation of resources or changes to our plans or strategy. The Group expressly disclaims any obligation to revise forward-looking statements made in this or other announcements to reflect changes in our expectations or circumstances. No reliance may be placed on the forward-looking statements contained within this announcement.

 

For further enquiries, please contact

Investors Sarah Pollard, PZ Cussons plc - Chief Financial Officer 0161 435 1000

Media Tim Linacre / Guy Scarborough / Bryn Woodward - Instinctif 020 7457 2020

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUAAURAKUKUUR
Date   Source Headline
24th Apr 20247:00 amRNSQ3 Trading and update on strategic actions
19th Apr 20248:49 amRNSDirector/PDMR Shareholding
12th Apr 202411:04 amRNSDirector/PDMR Shareholding
8th Apr 20245:29 pmRNSDirector/PDMR Shareholding
19th Mar 202410:30 amRNSDirector/PDMR Shareholding
23rd Feb 20243:47 pmRNSDirector/PDMR Shareholding
19th Feb 20243:18 pmRNSDirector/PDMR Shareholding
8th Feb 20243:40 pmRNSDirector/PDMR Shareholding
8th Feb 20243:09 pmRNSDirector/PDMR Shareholding
8th Feb 20243:07 pmRNSDirector/PDMR Shareholding
7th Feb 20247:00 amRNS2024 Interim Results
19th Jan 202410:50 amRNSDirector/PDMR Shareholding
15th Jan 20247:00 amRNSDirectorate Change
18th Dec 20233:10 pmRNSDirector/PDMR Shareholding
4th Dec 20233:03 pmRNSDirector/PDMR Shareholding
4th Dec 20237:00 amRNSDirectorate Change
29th Nov 202312:10 pmRNSDirector/PDMR Shareholding
29th Nov 202312:08 pmRNSDirector/PDMR Shareholding
23rd Nov 20235:57 pmRNSResult of AGM
23rd Nov 20237:00 amRNSAGM Trading Statement
20th Nov 20231:58 pmRNSDirector/PDMR Shareholding
19th Oct 202310:00 amRNSDirector/PDMR Shareholding
10th Oct 202311:10 amRNSDirector/PDMR Shareholding
5th Oct 20233:44 pmRNSHolding(s) in Company
27th Sep 202310:00 amRNSPreliminary Results - Correction
26th Sep 20237:00 amRNSPZ Cussons Preliminary Results
20th Sep 202311:09 amRNSDirector/PDMR Shareholding
5th Sep 20237:00 amRNSAcquisition of minority ownership of PZCN Plc
21st Aug 20232:07 pmRNSDirector/PDMR Shareholding
26th Jul 20239:22 amRNSDirector/PDMR Shareholding
19th Jul 202310:23 amRNSDirector/PDMR Shareholding
11th Jul 20232:06 pmRNSDirector/PDMR Shareholding
4th Jul 20237:00 amRNSCapital Markets Event
30th Jun 20232:18 pmRNSDirector/PDMR Shareholding
29th Jun 202311:06 amRNSDirector/PDMR Shareholding
27th Jun 20237:00 amRNSTrading Statement
21st Jun 20239:59 amRNSDirector/PDMR Shareholding
16th Jun 20237:00 amRNSDirectorate Change
19th May 20239:27 amRNSDirector/PDMR Shareholding
21st Apr 20239:00 amRNSIntention to Conduct Audit Tender
19th Apr 202310:01 amRNSDirector/PDMR Shareholding
13th Apr 20233:18 pmRNSHolding(s) in Company
13th Apr 20237:00 amRNSQ3 Trading Update
12th Apr 20232:18 pmRNSDirector/PDMR Shareholding
24th Mar 20237:00 amRNSDirectorate Change
21st Mar 20239:30 amRNSDirector/PDMR Shareholding
17th Mar 20234:35 pmRNSPrice Monitoring Extension
21st Feb 20239:31 amRNSDirector/PDMR Shareholding
8th Feb 20237:00 amRNS2023 Interim Results
19th Jan 20234:20 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.